ArGEN-X Enters Long-term Strategic Alliance With Shire Pharmaceuticals in Therapeutic Antibodies

June 4, 2014

BREDA, the Netherlands, June 4, 2014 /PRNewswire/ –


arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing
differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune
diseases, today announced it has entered into a long-term strategic alliance with Shire
Pharmaceuticals. Under the agreement, arGEN-X will bring its entire suite of human
antibody discovery technologies to a partnership focused on multiple targets aligned with
Shire’s therapeutic focus. The multi-year initiative aimed at helping augment the Shire
development pipeline follows an initial research and development collaboration undertaken
in March 2012.

“Our partnering philosophy at arGEN-X is to create alliances for the long term with
select, top tier companies. We have certainly upheld this principle by repeatedly
expanding our collaboration with Shire, with today’s announcement marking our most
ambitious and exciting venture with them to date,” said Tim Van Hauwermeiren, CEO of
arGEN-X. “We have enjoyed consistent success in our collaboration, recognizing important
synergies in combining our strengths and capabilities. While we continue to see Shire as
our development partner in this new alliance, we value this opportunity to bring programs
into our own pipeline to further our ambitions as a clinical stage, product-focused

Shire will make a total upfront investment of EUR15 million (US$20.4 million) in
arGEN-X, consisting of EUR3 million in cash and EUR12 million in equity. In addition, it
will fund the collaborative research programs at arGEN-X and pay fees, clinical,
regulatory and sales milestones, as well as single digit royalties on therapeutic product
sales. Shire will be responsible for clinical development and commercialization of
products, with arGEN-X having the right to license any programs not pursued by Shire into
its own development pipeline.

Dr. Philip J. Vickers, Global Head of Research and Development at Shire commented:
“Our arGEN-X collaboration has exceeded our expectations in delivering highly
differentiated antibody programs within our therapeutic focus. The time is right to commit
more significantly to the company through a longer term investment in its unique, world
class technologies”.

About arGEN-X

arGEN-X is a clinical-stage biopharmaceutical company focused on creating and
developing differentiated therapeutic antibodies for the treatment of cancer and severe
autoimmune diseases. arGEN-X has generated a clinical pipeline of differentiated antibody
candidates using its SIMPLE Antibody(TM) discovery platform. SIMPLE Antibody(TM) has a
particular strength in addressing novel, complex disease targets that are difficult to
access using established antibody technology platforms. Fc engineering technologies -
NHance(R), ABDEG(TM) and POTELLIGENT(R) – further enhance the therapeutic properties of
SIMPLE Antibody(TM) leads in terms of their residence time in the body, their ability to
clear disease targets or pathogenic antibodies and their cell killing potency through
Antibody-Dependent Cell-mediated Cytotoxicity (ADCC), respectively. arGEN-X has leveraged
its suite of antibody technologies in forging strategic collaborations with pharmaceutical
and biotechnology companies to provide new approaches to diseases with unmet medical



Source: PR Newswire

comments powered by Disqus